Novartis Pharma has entered an exclusive worldwide licensing agreement with China-based biotechnology firm BoomRay Pharmaceuticals for an undisclosed preclinical radioligand therapy asset. The transaction, valued at up to $900m, secures
Gene Therapy
2Articles
The United States Food and Drug Administration has granted approval for Waskyra, marking a significant milestone as the first gene therapy authorised for the treatment of Wiskott-Aldrich syndrome. The therapy,